A Phase 1/2 Study of Carfilzomib As a Replacement for Bortezomib for Multiple Myeloma (MM) Patients (pts) Refractory to a Bortezomib-Containing Combination Regimen
James R. Berenson(Oncotherapeutics (United States)), Robert Vescio(Royal Adelaide Hospital), James Hilger, Youram Nassir, Donald Gravenor, Dipti Patel‐Donnelly(Orthopaedic Research of Virginia), Alberto Bessudo(California Cancer Associates for Research and Excellence), Laura Stampleman, Ralph V. Boccia(Center for Cancer and Blood Disorders), Regina A. Swift(Institute for Myeloma & Bone Cancer Research), Robert Dichmann, Shahrooz Eshaghian(Cedars-Sinai Medical Center)
Cited by 1
Related Papers
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Assessment of thymic output in adults after haematopoietic stemcell transplantation and prediction of T-cell reconstitution
|The Lancet|2000|579
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425